These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22901018)

  • 41. The Canada Pension Plan's experience with investing its portfolio in equities.
    Sarney M; Preneta AM
    Soc Secur Bull; 2001-2002; 64(2):46-56. PubMed ID: 12428509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. American Recovery and Reinvestment Act-comparative effectiveness research infrastructure investments: emerging data resources, tools and publications.
    Segal C; Holve E
    J Comp Eff Res; 2014 Nov; 3(6):647-55. PubMed ID: 25494571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Institutional obstacles to expansion of world food production.
    Crosson PR
    Science; 1975 May; 188(4188):519-24. PubMed ID: 17740002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding?
    Gandjour A
    Pharmacoeconomics; 2011 Jul; 29(7):555-61. PubMed ID: 21534639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative effectiveness research: from clinical information to economic incentives.
    Robinson JC
    Health Aff (Millwood); 2010 Oct; 29(10):1788-95. PubMed ID: 20921477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Private investment in hospitals: a comparison of three healthcare systems and possible implications for real estate strategies.
    van der Zwart J; van der Voordt T; Jonge Hd
    HERD; 2010; 3(3):70-86. PubMed ID: 21165862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bringing liraglutide to market: a CER case study.
    Oderda G; Sifford-Wilson SM
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S12-8. PubMed ID: 22663295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development: description of a successful public-private sector international collaboration.
    Bronnenkant L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S311-3. PubMed ID: 7865329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe.
    Koenig P; Macgarvie M
    J Health Econ; 2011 Sep; 30(5):950-65. PubMed ID: 21899905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Excavating treasure from the amber of the prior art: why the public benefit doctrine is ill-suited to the pharmaceutical sciences.
    Hess RA
    Food Drug Law J; 2011; 66(1):105-20, iii. PubMed ID: 24505849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementing CER: what will it take?
    Biskupiak JE; Dunn JD; Holtorf AP
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S19-29. PubMed ID: 22663296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The methods of comparative effectiveness research.
    Sox HC; Goodman SN
    Annu Rev Public Health; 2012 Apr; 33():425-45. PubMed ID: 22224891
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.